◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocks0-9 › 1548

Genscript Biotech Corporation (1548) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-11

Genscript Biotech Corporation (1548) operates in the Biotechnology industry and is headquartered in Wan Chai, Hong Kong with about 6,165 employees. Its market capitalization is roughly $54 billion. In the fiscal year ended 2025-12-31, 1548 reported $960M in revenue and ($533M) in net income.

Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally.

Interactive charts & full statements →

1548 Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-31
Total Revenue$960M$594M$560M$626M
Gross Profit$553M$272M$271M$304M
Operating Income (EBIT)$262M$23M$40M($428M)
Net Income($533M)$3.0B($96M)($227M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

1548 Free Cash Flow History

1548 Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$4.9B$5.3B$3.4B$2.5B
Total Liabilities$889M$955M$1.3B$1.2B

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 1548 viewer.

Other Companies in Biotechnology

← 1547All “0-9” companies1549 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.